The information on this page about projects and other funding data may not be exhaustive for reasons of confidentiality and intellectual and industrial property protection. If you need more complete information, please contact the institution.

16 funding €4,784,322.00

data available since 2018
filter_list

2025

  1. Therapeutic OligonUCleotides Activated by Nucleases: Targeted antibiotics for bacterial infections (TOUCAN-MRSA)

    €995,000.00

  2. Overcoming resistance to virotherapy for pediatric brain tumors

    €154,000.00

  3. Harness lncRNA targeting to enhance treatment for colorectal cancer. TARCO

    €51,000.00

2024

  1. Uncovering resistance mechanism to CAR-T cells via deep learning in scRNAseq for improved therapies

    €359,500.00

  2. Uncovering resistance mechanism to CAR-T cells via deep learning in scRNAseq for improved therapies

    €309,650.00

  3. LncRNAs modulating DNA damage and repair: towards novel therapies for hepatocellular carcinoma

    €394,903.00

  4. Generation of humanized organs from human iPS cells.

    €500,026.00

2023

  1. Overcoming resintance to virotherapy for pediatric brain tumors. PANDA

    €50,000.00

2021

  1. ACTILNET. INTERLEUKIN-8 AND NEUTROPHIL EXTRACELULAR TRAPS AS ACTIONABLE HURDLES FOR CANCER IMMUNOTHERAPY

    €498,850.00

  2. lncRNAs-RS-CRC. Understanding lncRNAs in replicative stress and colorectal cancer: from cancer biology to single-molecules

    €375,000.00

  3. Niños Contra el Cáncer (3 Convenio FDBLC)

    €100,000.00

2020

  1. HR20-00871 GR-NET NORMAL-HIT David Lara

    €153,850.00

  2. Gene Regulatory NETworks in NORmal and MALignant Hematopoiesis- Identification and Targeting (GR-NET NORMAL-HIT

    €411,250.00

  3. Riboswitches On U1 snRNP for Therapeutic Expression Regulation

    €70,000.00

  4. PLA2G4E: a new target for dementia treatment

    €70,000.00

2018

  1. A live imaging approach to investigate tumor immunology and immunotherapy in a translational arena

    €291,293.00

The information on this page about projects and other funding data may not be exhaustive for reasons of confidentiality and intellectual and industrial property protection. If you need more complete information, please contact the institution.